Inhibrx Biosciences CEO Mark Lappe acquires $984,588 of common shares

INBX•2026-09-28

CEO Mark P. Lappe reported open-market purchases of Inhibrx Biosciences shares through the Lappe Family Trust. The trust’s holdings rose to 740,548 shares; separate indirect holdings included 165,000 shares in the Lappe Descendants’ Trust and 54,865 shares in Lappe’s Roth IRA.

Inhibrx Biosciences CEO Mark Lappe acquires $984,588 of common shares

1. Purchase and holdings

Related News

Revolution Medicines commercialization chief Anthony Mancini sells $743,436 in common shares

Agroz profit for year jumps to MYR 6.58 million in 2025; revenue rises 79% to MYR 73.13 million

NeOnc Technologies schedules FDA end-of-Phase 1 meeting for NEO212

Sources

Inhibrx Biosciences CEO Mark Lappe acquires $984,588 of common shares

StandardAero COO Kimberly Ernzen steps down effective Sept. 28

China risks swinging the tax pendulum too far